Want 98% to 148% Returns This Year? Wall Street Says Buy These 3 Stocks


Wall Street doesn't always get it right. Some stocks that analysts really like don't perform well. Others that they dislike can be surprising stars.

However, analysts spend a lot of time poring over companies' financial reports and researching their businesses and industry trends. They do plenty of number crunching to come up with price targets for stocks. 

It's probably fair to say that the stocks that analysts are most bullish about have at least reasonable prospects of generating solid gains. And some of those stocks could be especially big winners. If you want returns of 98% to 148% this year, Wall Street analysts think that buying these three stocks could do the trick.

Want 98% to 148% Returns This Year? Wall Street Says Buy These 3 Stocks

Image source: Getty Images.

1. Shopify 

Shopify (NYSE:SHOP) is an e-commerce leader that analysts really like these days. The stock delivered a 22% gain in 2021. Wall Street's consensus price target for Shopify is 148% higher than the current share price.

Sure, Shopify's valuation might seem terrifyingly high. The stock trades at almost 44 times sales and nearly 278 times expected earnings. However, it's important to put this premium valuation into context.

The total addressable market for Shopify in serving small- to medium-sized businesses (SMB) is more than $150 billion per year. Shopify isn't limited to the SMB market, though. The company also caters to entrepreneurial start-ups and large customers. 

Shopify is growing rapidly, with revenue soaring 46% year over year in its latest reported quarter. The company will need to avoid missteps (such as the recent changes to its app store that displeased customers) to keep that momentum going. Barring any major blunders in the future, Shopify should be in a good position to deliver impressive returns for investors in 2022.

2. Sea Limited

If 2021 had ended in October, Sea Limited (NYSE:SE) would have delivered a sizzling gain last year. However, the stock plunged in the final couple of months and ended the year up only 12%.

But Wall Street analysts think that Sea could make a major comeback in 2022. The average price target for the stock reflects an upside potential of 140%. There are several reasons to be optimistic about the prospects for Sea to double or more this year.

Sea's Free Fire mobile game continues to pick up momentum -- and not just in Southeast Asia, where it has dominated for several years. It's also the highest-grossing mobile game in Latin America. Free Fire ranks as the highest-grossing mobile battle royale game in the U.S. and the second highest-grossing mobile game overall on Google Play.

Don't think of Sea Limited as only a video game stock, though. The company also stands as a leader in e-commerce with its Shopee platform. Shopee is the top e-commerce app in Southeast Asia, Indonesia, and Taiwan. It's gaining traction in Latin America as well, especially in Brazil. Sea's mobile wallet payment volume has also increased tremendously thanks in large part to Shopee's success.

There aren't many companies that claim leading positions in gaming, e-commerce, and digital payments. All three are key trends with lots of growth potential. Perhaps Sea Limited won't live up to analysts' expectations this year, but it won't be surprising if it does.

3. Teladoc Health

Some might be tempted to throw in the towel on Teladoc Health (NYSE:TDOC). Shares of the virtual care provider lost more than half of its market cap last year. However, analysts remain very bullish about Teladoc. The average price target for the stock reflects a premium of 98% to the current share price.

Teladoc doesn't have to look very far to find growth opportunities. The company currently has 76 million members. There are another 16 million potential members at existing clients who haven't enrolled in Teladoc's virtual care offerings. And there are an additional 63 million individuals within existing clients that don't yet have access to any of Teladoc's products. 

Increased product penetration is another way for Teladoc to grow. The penetration rate for the company's chronic disease management platform for diabetes is only around 21% right now. Less than 1% of members currently use Teladoc's new Primary360 virtual primary care product. 

Of course, Teladoc also has significant room for bringing on new customers. More than 140 million Americans don't use Teladoc yet.

Consulting firm McKinsey & Company estimates that the U.S. virtual care market could reach up to $250 billion per year. Teladoc is the leader in this market and should retain its position despite increased competition. Maybe the stock won't nearly double this year as Wall Street expects. However, Teladoc should be able to deliver huge gains over the long run. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.